Bio-Techne Corp [TECH] stock prices are up 0.83% to $48.33 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TECH shares have gain 3.58% over the last week, with a monthly amount drifted -4.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on April 09, 2025, when KeyBanc Capital Markets downgraded its rating to a Sector Weight. Previously, Evercore ISI started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $75. On February 19, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $68 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $85 on May 22, 2024. Scotiabank initiated its recommendation with a Sector Outperform and recommended $80 as its price target on February 08, 2024. Stifel downgraded its rating to Hold for this stock on February 02, 2024, but kept the price target unchanged to $65. In a note dated December 07, 2023, UBS initiated an Buy rating and provided a target price of $80 on this stock.
The stock price of Bio-Techne Corp [TECH] has been fluctuating between $46.01 and $83.62 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $48.33 at the most recent close of the market. An investor can expect a potential return of 55.18% based on the average TECH price forecast.
Analyzing the TECH fundamentals
The Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.21B for trailing twelve months, representing a surge of 4.20%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.88 points at the first support level, and at 47.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.83, and for the 2nd resistance point, it is at 49.33.
Ratios To Look Out For
It’s worth pointing out that Bio-Techne Corp [NASDAQ:TECH]’s Current Ratio is 3.71. On the other hand, the Quick Ratio is 2.58, and the Cash Ratio is 0.83. Considering the valuation of this stock, the price to sales ratio is 6.27, the price to book ratio is 3.75 and price to earnings (TTM) ratio is 58.91.
Transactions by insiders
Recent insider trading involved Herr Amy E., Director, that happened on Feb 14 ’25 when 1860.0 shares were sold. Domestic Partner of Director, JOSHUA MOLHO completed a deal on Feb 14 ’25 to buy 1860.0 shares. Meanwhile, Chief Executive Officer Kelderman Kim sold 13392.0 shares on Jan 27 ’25.
